Biotech

All Articles

Actinogen's cortisol blocker neglects phase 2 clinical depression research study

.Actinogen Medical's cortisol blocker has missed the primary endpoint of a stage 2 research study in...

Bivictrix determines going private only way to take ADC into clinic

.Antibody-drug conjugates (ADCs) have been at the facility of numerous a billion-dollar biobuck lice...

TPG tops up funds to $580M for assets around lifestyle scientific researches

.Possession manager TPG, which has actually sustained biotechs like Sionna Rehabs as well as Santa A...

Merck ceases period 3 TIGIT trial in lung cancer for futility

.Merck &amp Co.'s TIGIT plan has suffered an additional misfortune. Months after shuttering a stage ...

After a difficult year, Exscientia folds up in to Recursion

.After a year defined through pipe hairstyles, the variation of its own CEO and also unemployments, ...

Cullinan, after $25M deal, hands back bispecific to Harbour

.Cullinan Therapy was actually wowed sufficient along with Harbour BioMed's bispecific immune activa...

A nearer check out Brutal Biotech's Strong 15

.In this full week's episode of "The Top Pipe," our team are actually diving into Intense Biotech's ...

Lilly encounters phase 2 failing of tau-targeting med

.The confetti is actually still soaring coming from Eli Lilly's celebration commemorating the commen...

Biogen CMO Maha Radhakrishnan participates in Sofinnova-- Chutes &amp Ladders

.Invite to recently's Chutes &amp Ladders, our roundup of significant management hirings, shootings ...

Lykos will certainly talk to FDA to reevaluate its own decision following denial of MDMA treatment for post-traumatic stress disorder

.Following a poor presenting for Lykos Therapies' MDMA prospect for post-traumatic stress disorder a...